FDA Approves Uptravi for Pulmonary Arterial Hypertension

Share this content:
FDA Approves Uptravi for Pulmonary Arterial Hypertension
FDA Approves Uptravi for Pulmonary Arterial Hypertension

TUESDAY, Dec. 22, 2015 (HealthDay News) -- Uptravi (selexipag) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension.

Uptravi, an oral IP prostacyclin receptor agonist, relaxes and opens blood vessels, easing the elevated pressure, the agency said.

The drug was evaluated in clinical trials involving 1,156 adults with pulmonary arterial hypertension. Trial participants who took the drug did so for an average of about a year and a half. The drug was found to limit worsening of the disease and reduce the need for hospitalization.

Uptravi's most common side effects included headache, diarrhea, jaw pain, nausea, myalgia, vomiting, pain in the arms and legs, and flushing.

The drug is marketed by San Francisco-based Actelion Pharmaceuticals.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »